Modified fluorinated nucleoside analogues

Patent metadata

Field	Value
Publication number	US-10287311-B2
Application number	US-85421807-A
Country	US
Kind code	B2
Filing date	Sep 12, 2007
Priority date	May 30, 2003
Publication date	May 14, 2019
Grant date	May 14, 2019

Abstract

The disclosed invention provides compositions and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially humans, using a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleosides, or a pharmaceutically acceptable salt or prodrug thereof.

First claim

I claim:

1. A method for the treatment of hepatitis C infection, which comprises:
providing to a human subject in need thereof an antivirally effective amount of a (2′R)-2′-deoxy-2′-fluoro-2′-C-methyl nucleoside (β-D) or its pharmaceutically acceptable salt of the structure:

wherein R 1 and R 7 are independently H, a monophosphate, a diphosphate, or a triphosphate; and
R 4 is NH 2 or OH.

Assignees

• Clark Jeremy
• Gilead Pharmasset Llc

Inventors

• Clark Jeremy

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/04

  Antibacterial agents · CPC title